The cannabis market has been growing with a massive amount of propensity toward the future for some time now. With new laws going into place around the world and a changing public perception on the plant as a whole, it seems as though now is a better time than ever to watch the cannabis space. Biotech stocks within the cannabis market have also been growing with a massive amount of energy into the future as new laws continue to favor cannabis as a choice over traditional drugs for everything from pain to nausea treatments.
One of the main stocks in the industry has been GW Pharmaceuticals (NASDAQ:GWPH) The company currently has a market cap of around $150 million which means that they are on the larger side of the industry, but still relatively in the middle when compared to other stocks in the space. The company has stated that their sales are expected to jump from around $20 million to over $150 million during the course of the next year. One research report states that this massive growth has mainly come from “the approval of cannabidiol-based drug Epidiolex on June 25 by the U.S. Food and Drug Administration (FDA). This therapy, which is the first cannabis-derived drug to get the green light from the FDA, is designed to treat two rare types of childhood-onset epilepsy known as Dravet syndrome and Lennox-Gastaut syndrome. Since there were no other FDA-approved treatments for Dravet syndrome prior to this approval, GW Pharmaceuticals looks to have a clear path to success.” The FDA’s approval of this drug also signaled a very large change in the industry as a whole as this was the first time that the governing body so unanimously decided to approve a cannabis-based drug. All in all, GW should remain on any investors watch list.
The next stock on the list is the company GT Biopharma (OTC:GTBP). According to one report, the company “GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates.” These medicines have become extremely popular as more and more realize the massive amount of potential when using cannabis to treat a wide variety of illnesses. The company has a market cap of around $100 million which also puts them in the medium-sized company space for the whole of the cannabis market. All in all, GT Biopharma remains an incredibly interesting stock to watch over the course of the next few years.
The last stock on the list and one that should be a household name in the industry by now is the company Cara Therapeutics (CARA). With a market cap of around $730 million, the company is on the higher side of the companies in the cannabis space. As a purely biopharmaceutical business, Cara Therapeutics is stated to be a “ company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus.” The company has continued to make revolutionary drugs using the cannabis plant, and continues to be a favorite among investors.
The hopes are high that the industry on cannabis can continue to fuel investments into the biotech sector as the massive amount of potential will hopefully drive even more growth in the near future.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com